global immunization meeting: protect, innovate, accelerate · location: tramuntana 1 & 2 chair:...

P

IA

PROTECT

ACCELER

ATE

INNOVATE

23-25 June 2015S ITGES, SPAIN

Global Immunization Meeting: Protect, Innovate, Accelerate

PROGRAMME COMMITTEE

24, rue Salomon de Rothschild - 92288 Suresnes - FRANCETél. : +33 (0)1 57 32 87 00 / Fax : +33 (0)1 57 32 87 87Web : www.carrenoir.com

GAVIGAI_14_6999_LogoRVB_GB11/07/2014

Ce fichier est un document d’exécution créé sur Illustrator version CS5.

ÉQUIVALENCE RVB / HTML

R149 V214 B0 / #95D600

R0 V92 B185 / #005CB9

R0 V161 B223 / #00A1DF

Table of Contents

Welcome .................................................................................................... 04

Acknowledgements ................................................................................... 06

Tuesday 23 June: ProtectAgenda .....................................................................................................................10Plenary session #1: Global Vaccine Action Plan goals .........................................12Plenary session #2: Achieving coverage and equity ............................................13Plenary session #3: Going beyond RED ................................................................14Working group #1: Aligning country assessments ..............................................16Working group #2: Driving and sustaining demand ...........................................18Working group #3: Sustainable access to vaccines .............................................20

Wednesday 24 June: InnovateAgenda .....................................................................................................................24Plenary session #4: Polio eradication ....................................................................26Plenary session #5: Immunization supply chain and logistics .............................27Plenary session #6: Pneumonia and diarrhoea control .......................................28Working group #4: Reaching older age groups ...................................................30Working group #5: Information systems ...............................................................34Working group #6: Game-changers in immunization delivery ...........................36

Thursday 25 June: AccelerateAgenda .....................................................................................................................40Plenary session #7: Maternal and neonatal tetanus elimination .........................42Plenary session #8: Measles and rubella elimination...........................................43Working group #7: MNT and measles/rubella elimination .................................44Working group #8: Immunization and post-emergency response .....................46Working group #9: Vaccine implementation lessons learned ............................48

Marketplace ............................................................................................... 50

Satellite meetings ...................................................................................... 52

List of participants ..................................................................................... 54

4 Global Immunization Meeting: Protect, Innovate, Accelerate

The objectives of the Global Immunization Meeting are to review and discuss among global, regional and country immunization partners, key issues related to strengthening routine immunization, to the implementation of new and under-utilized vaccines and to accelerated disease control efforts – notably for measles, rubella and maternal and neonatal tetanus – including alignment with polio eradication efforts.

Meeting objectivesThis year, particular consideration and review will be given to the following issues:

• Technical updates on new strategies for reaching unreached populations with routine vaccination, and discussions on major opportunities and challenges with new approaches.

• Review of activities and lessons learned from countries and regions in the implementation of new vaccines, and preparation of countries for the successful introductions of new vaccines in 2015.

• Discussion of innovative approaches for achieving measles, rubella and tetanus elimination including newly-developed guidance for supplementary immunization activities, and new vaccine delivery technologies.

• Exchange of information between WHO, UNICEF and other immunization partners - at all levels - on respective roles and responsibilities in the provision of technical assistance to countries.

Welcome

Expected outcomes • Update on programmatic achievements

including progress with implementation of strategies to increase routine coverage, to introduce new vaccines with an enhanced focus on integrated approaches to disease control, specifically in the context of pneumococcal, rotavirus, Measles/Rubella and HPV vaccines.

• Member States, WHO and UNICEF Regional and Country Office staff and partners better informed on new strategies for increasing immunization coverage, on new vaccines implementation and on the latest guidance for accelerated disease control.

• A Meeting Programme Committee with representation of EPI partners (WHO, UNICEF, BMGF, Gavi, US CDC, JSI, IFRC) has jointly developed the agenda based on review and independent scoring of suggested topics in the three priority areas: ‘Protect’ (reach the unreached, increase and sustain coverage and strengthen immunization systems), ‘Innovate’ (introduce new vaccines and technologies and promote integrated approaches to disease control) and ‘Accelerate’ (eliminate measles and rubella, control meningitis A and monitor maternal and neonatal tetanus elimination).

23-25 June 2015 Sitges, Spain 5

Meeting format• The three-day meeting is

scheduled for 23rd to 25th June 2015 in Sitges, Spain and will be co-hosted by WHO Headquarters, the WHO European Region, and UNICEF.

• The meeting will combine plenary and parallel workshop sessions on key EPI topics. Keynote addresses will further investigate overriding meeting themes for each day.

• Workshop facilitators have developed objectives and a proposed structure with expected outcomes for the relevant sessions and feedback will be provided and discussed in plenary by workshop rapporteurs. On the final day of the meeting a summary of the main meeting outcomes will be given and next steps identified which will be required to advance the global immunization agenda.

Sitges harbour, Spain


Such an event cannot be organized singlehandedly. It is important to acknowledge the people and groups who have made this conference possible.

SecretariatRudi Eggers (WHO)

Katia Gaudin-Billaudaz (WHO)

Carsten Mantel (WHO)

Gill Mayers (WHO)

Peter Strebel (WHO)

Acknowledgements

Programme CommitteeNihal Abeysinghe (WHO)

Robb Butler (WHO)

Diana Chang-Blanc (WHO)

Alya Dabbagh (WHO)

Amy Dietterich (IFRC)

Rudi Eggers (WHO)

Rebecca Fields (JSI)

Marta Gacic-Dobo (WHO)

Ben Hickler (Unicef)

Henri van den Hombergh (UNICEF)

Terri Hyde (US CDC)

Robert Kezaala (UNICEF)

Philipp Lambach (WHO)

Stefano Malvolti (Gavi)


Helen Matzger (BMGF)

Gill Mayers (WHO)

Liudmila Mosina (WHO)

Peter Strebel (WHO)

Carol Tevi-Benissan (WHO)

Michel Zaffran (WHO)


Agenda sessions

Tuesday

Anneline Blankenhorn (WHO)

Thomas Cherian (WHO)

Heather Deehan (UNICEF)

Rudi Eggers (WHO)

Rebecca Fields (JSI)

Tracey Goodman (WHO)

Rebecca Martin (US CDC)

Lisa Menning (WHO)

Richard Mihigo (WHO)

Aaron Wallace (US CDC)

Michel Zaffran (WHO)

Wednesday

Alan Brooks (Gavi)

David Brown (UNICEF)

Diana Chang Blanc (WHO)

Carolina Danovaro (WHO)

Birgitte Giersing (WHO)

Jan Grevendonk (WHO)

Phanuel Habimana (WHO)

Karen Hennessey (WHO)

Henri van den Hombergh (UNICEF)

Debbie Kristiansen (PATH)


Thursday

Pankaj Bhatnagar (WHO)

Robb Butler (WHO)

Tracey Goodman (WHO)

Matt Hanson (BMGF)

Terri Hyde (US CDC)

Robert Kezaala (UNICEF)

Katrina Kretsinger (US CDC)

Rebecca Martin (US CDC)

Richard Mihigo (WHO)

Peter Strebel (WHO)

Ahmadu Yakubu (WHO)

MarketplaceGill Mayers (WHO)

Lisa Menning (WHO)

Conference GuideDan Brigden (WHO)

Rebecca Richards-Diop (RRD Design)

And finally...The Global Immunization Meeting would not have been possible without the generous funding of the Bill & Melinda Gates Foundation.

PROTECT

TUESDAY

23JUNE

Location: Tramuntana 1 & 2 Chair: Michel Zaffran (WHO)

10

TUESDAY

23JUNE


Plenary session agenda 08:00 - 12:30

TIME PLENARY SESSION

07:30 - 08:15 Registration in Hall Tramuntana

08:30 – 09.00 Welcome addresses• Elena Andradas,Subdirector of Health Promotion and Epidemiology,

Ministry of Health, Social Services and Equity, Spain• Jean-Marie Okwo-Bele, WHO • Henri van den Hombergh, UNICEF

09:00 – 09:30

Plenary session #1

Page 12

Are we on track to achieve the Global Vaccine Action Plan goals? Rebecca Martin, US CDC

To get the GVAP back on track, action needs to focus on addressing five priority problems: weak GVAP implementation, poor data quality and use, vaccine affordability and supply, failures of basic integration and situations disrupting immunization. Each problem is major, but each can be tackled, with reasonable expectation that doing so will improve progress considerably.

09:30 -10:00

Plenary session #2

Page 13

Achieving coverage and equity Orin Levine, Gates Foundation

Keynote highlighting the need for robust and good quality routine immunization services to act as foundation for the entire immunization programme, promoting nine transformative investments of the Global Routine Immunization Strategies and Practices (GRISP) and recommitting all to reaching the GVAP coverage goals.

10:00 - 10:30 Coffee break

10.30 – 11.30

Plenary session #3

Page 14

Going beyond RED • The routine immunization systems strengthening landscape, including

GRISP and Gavi 4.0 coverage and equity focus (Alan Brooks, Gavi)• Successful approaches to reaching the fifth child, tools to reduce equity

gaps (Richard Duncan, UNICEF)• Community ownership and engagement (Robert Steinglass, JSI; Sharmin

Zahan, BRAC)• Case study on community engagement: Madagascar (Benjamin

Andriamitsantsoa, Madagascar)

11.30 - 12.00 Discussion

12.00 - 12.30 Keypad quiz and teasers for afternoon group session


TUESDAY

23JUNE

Working group agenda 14:00 - 17:30

GROUP # WORKING GROUP FACILITATORS

Working group #1

Page 16

Towards aligning country assessments• Global perspective on immunization programme

assessments (Carsten Mantel, WHO)• Lao and Tanzania perspectives and experiences

with implementing assessments and recommendations (Anonh Xeuatvongsa, Lao PDR; Dafrossa Lyimo, Tanzania)

• Opportunities to harmonize assessments

Richard Mihigo, WHO

Aaron Wallace, US CDC

Working group #2

Page 18

Promising practices in driving and sustaining demand • Vaccination demand: Key concepts, definitions, and

indicators – and system , community and individual factors (Benjamin Hickler, UNICEF; Robb Butler, WHO)

• Hearing and acting upon the community voice/agenda – the role of CSOs (Amy Dietterich, IFRC)

• Testing the definition and SO2 indicator (Rebecca Martin, US CDC)

• Promising practices in driving demand, listening to the community and closing the immunity gap – flash country presentations (Sharmin Zahan, BRAC; Geert Top, Belgium; Ann Lindstrand, Sweden; Tsamo Louis Merlin, Cameroon)

Rebecca Martin, US CDC

Rebecca Fields, JSI

Lisa Menning, WHO

Working group #3

Page 20

Sustainable access to vaccines in middle-income countries• A partner-shared MIC strategy (Anneline Blankenhorn,

WHO) • Gavi Alliance’s work with MICs (Judith Kallenberg,

Gavi)• Timely access to affordable vaccines for MiCs (Heather

Deehan, UNICEF)• Sustainable immunization financing (Niyazi Cakmak,

WHO) • Case study: Indonesia (Yosephine Prima Berliana)

Michel Zaffran, WHO

Heather Deehan, UNICEF

15.30 - 16.00 Coffee break

18.00 - 19.30 Cocktail reception

OutlineIn May 2012, the Sixty-fifth World Health Assembly endorsed the global vaccine action plan and requested the Director-General to monitor progress and report annually, through the Executive Board, to the World Health Assembly, on progress towards achievement of global immunization targets using an independent review process: the Strategic Advisory Group of Experts on Immunization (SAGE).

SAGE noted that there has been success in introducing new vaccines, and positive achievements in numerous countries in several areas, including the establishment and strengthening of National Immunization Technical Advisory Groups.

However, progress is far off-track. Five of the six goals set by the GVAP with deadlines at the end of 2014 or 2015 still require substantial progress to get the goals on track (poliovirus transmission interruption, maternal and neonatal tetanus, measles and rubella elimination, and DTP3 coverage targets). Indeed, most have seen very little progress. Some have been missed multiple times before.

To get the GVAP back on track, the SAGE recommends that action focus particularly on addressing five priority problems:

• Weak GVAP implementation

• Poor data quality and use

• Vaccine affordability and supply

• Failures of basic integration

• Situations disrupting immunization

Each problem is major, but each can be tackled, with a reasonable expectation that doing so will improve progress considerably.

Resources• Global Vaccine Action Plan:

www.who.int/immunization/global_vaccine_action_plan

• GVAP Secretariat Report 2014: www.who.int/entity/immunization/global_vaccine_action_plan/gvap_secretariat_report_2014.pdf

• SAGE GVAP Assessment Report 2014: www.who.int/entity/immunization/global_vaccine_action_plan/SAGE_DoV_GVAP_Assessment_report_2014_English.pdf

Chair Michel Zaffran, WHO

Rapporteur Thomas Cherian, WHO

Speaker Rebecca Martin, US-CDC /GID on behalf of the SAGE GVAP working group WHO IVB

Are we on track to achieve Global Vaccine Action Plan goals?

12

Tuesday 23 June, 09:00 – 09:30

Plenary session #1


http://www.who.int/immunization/global_vaccine_action_plan

http://www.who.int/entity/immunization/global_vaccine_action_plan/gvap_secretariat_report_2014.pdf

http://www.who.int/entity/immunization/global_vaccine_action_plan/gvap_secretariat_report_2014.pdf

http://www.who.int/entity/immunization/global_vaccine_action_plan/SAGE_DoV_GVAP_Assessment_report_2014_Engl

http://www.who.int/entity/immunization/global_vaccine_action_plan/SAGE_DoV_GVAP_Assessment_report_2014_Engl

OutlineKeynote on achieving effective coverage and equity targets and routine immunization strategies (including GRISP) – from RED to REC – with input from country or Region.

ObjectivesThe objective of the session is to set the scene for the PROTECT day, where all topics and side meetings are focussed on issues of routine immunization systems strengthening and coverage improvement. Specific objectives:

• Highlight the need for robust and good quality routine immunization services to act as foundation to the entire immunization programme;

• Link the immunization programme to the overall health system;

• Within specific disease control goals (eg polio eradication), emphasize the necessity pivotal role of RI strengthening;

• Promote nine transformative investments of GRISP;

• Pursue the recommitment of all to reaching the GVAP coverage goals.

Outcomes By the end of the session, the participants should be able to endorse the central position that the routine immunization programme holds in reaching morbidity and mortality reduction goals of vaccine-preventable diseases.

Discussion areas• Relationship between RI and campaigns

• Funding support (or lack thereof) for RI services, both domestic and external

• GRISP related questions


Rapporteur Rudi Eggers, WHO

Speaker Orin Levine, Gates Foundation

Achieving effective coverage and equity targets and routine immunization strategies


Tuesday 24 June, 09:30 – 10:00

Plenary session #2

OutlineReaching undervaccinated children are a key strategy within GVAP and a critical component in making the GVAP guiding principle of equity real. A companion document to GVAP focussing on RI strategies and practices has been developed, containing a comprehensive overview of RI strategies. It also describes eight transformative investments, with the intent of directing global immunization focus in key areas that would modernize RI. At the same time Gavi has placed “Coverage and Equity” strategies at the centre of its strategic plan for 2016 – 2020.

This session will focus on two specific components of reaching undervaccinated children:

• Going beyond RED to identify and reach every community especially those that have been left out of services or are in marginalized parts of the society;

• Focussing on community engagement as a key to success in reaching all.

The session will contain overview presentations on these two components and a country example. Both the “Global Routine Immunization Strategies and Practices” (GRISP) document, the eight transformative investments outlined in GRISP and the Gavi 4.0 focus on “Coverage and Equity” should be contained in the overview presentations.

Discussion areas• How does this relate to RED strategies, in which situations do we need to go beyond RED?

• What role do global partners play in the activities that relate to community engagement at community level?

• How can the transformative investments in GRISP be used to further RI?

• How can RI opportunities be incentivised/created by funders at country level and then be implemented?

• How can the momentum in the Gavi 4.0 strategy be used to improve global coverage


Rapporteur Rebecca Fields, JSI

Speakers Alan Brooks, Gavi SecretariatRichard Duncan, UNICEFSharmin Zahan, BRACBenjamin Andriamitsantsoa, MoP Madagascar

Going beyond RED

14

Tuesday 23 June, 10:30 – 11:30

Plenary session #3


TIME TOPIC SPEAKER / FACILITATOR

10:30 - 10:40 Introductory comments to describe the RI system strengthening landscape, including GRISP and Gavi 4.0 coverage and equity focus

Alan Brooks

10:40 - 10:55 Successful approaches to reaching the fifth child, tools to reduce equity gaps

Richard Duncan

10:55 - 11:05 Discussion

11:05 - 11:20 Community ownership and engagement to achieve immunization goals

Sharmin Zahan Robert SteinglassAmy Dietterich

11:20 - 11:35 Case study on community engagement: Madagascar Benjamin Andriamitsantsoa


Detailed agenda


Tuesday 23 June, 10:30 – 11:30

Plenary session #3

BackgroundCountries are required to conduct an excessive number of assessments. Cumulatively these assessments equate to many months of planning and implementing each year and disrupt the programme’s core activities. Some of these assessments are redundant and may have limited added value or impact on country programmes.

Objectives• Identify and agree upon ways to increase the efficiency and decrease the burden of

assessments on country programs

• Draft next steps for aligning country assessments. The success of achieving session objectives requires having the right participants in the session – including those who can provide country perspectives & partner representatives who are familiar with assessment origins/requirements and who can propose and follow-through on actions.

OutcomesFor the 3 assessment themes (general reviews, vaccine management, data quality), present ideas and actions for increasing efficiency/decreasing burden. These can include to harmonize with other assessment, decrease frequency of assessment, decrease the scope, decrease the amount of time needed for preparation and conduct, allowing decision whether and when to conduct assessment to be driven by national planning process and ICC, alignment of recommendations and plans generated from assessment – especially with regards integrating into annual work plan and cMYP.

Discussion areasThe discussion areas will be in the form of plenary and break-out group discussion. The three break-out groups will be asked to discuss and present in plenary opportunities and next steps for aligning assessments.

Chair Richard Mihigo, WHO

Rapporteur Aaron Wallace, US CDC

Facilitators General EPI Programme Reviews: Karen Hennessey (WHO), Carolina Danovaro (WHO), Terri Hyde (US CDC) Vaccine Management Related Assessments: Diana Chang-Blanc (WHO), Heather Deehan (UNICEF)Data Quality Related Assessments: Jan Grevendonk (WHO), David Brown (UNICEF), Chung-won Lee (Gavi)Country Presentations: Anonh Xeuatvongsa (Lao PDR), Dafrossa Lyimo (Tanzania)

Towards aligning country assessments

16

Tuesday 23 June, 14:00 – 17:30

Working group #1


Detailed agenda


14:00 – 14:15 Global perspective on programme assessments Carsten Mantel

14:15 – 14:30 Experience with implementing assessments and recommendations in Lao PDR

Anonh Xeuatvongsa

14:30 - 14:45 Plans for harmonizing assessments and linking with cMYP in 2015, Tanzania

Lyimo Dafrossa

14:45 – 15:15 Discussion -- including when is alignment good and when is it too much?

Richard Mihigo

15:15 – 15:45 Coffee break

15:45 – 16:30 Break-out on opportunities and next steps to align assessments: EPI Programme Review (Carolina Danovaro,WHO; Terri Hyde, US CDC) Vaccine Management (Diana Chang-Blanc, WHO; Heather Deehan, UNICEF) Data Quality (David Brown, UNICEF, Chung-won Lee, Gavi)

Karen Hennessey

16:30 – 17:00 Report back from 3 groups (10 min each)

17:00 – 17:30 Discussion Richard Mihigo


Tuesday 23 June, 14:00 – 17:30

Working group #1

BackgroundThe second strategic objective (SO2) of the Global Vaccine Action Plan (GVAP) calls for “individuals and communities [to] understand the value of vaccines and demand immunization as both a right and a responsibility.” A GVAP SO2 working group was established to develop the understanding of “demand” (definition, components, actors, and determinants) and to explore means for measuring progress in this Strategic Objective during the Decade of Vaccines (DoV). This session will review the progress made by that Working Group, build consensus and understanding around the term demand and its determinants, share promising practices from across the globe and directly inform the review of the SO2 indicators, in doing so assisting the development of the demand-generation components of regional vaccine action plans and the preparation of a paper to be submitted to the October 2015 GAVI Alliance PPC (Program and Policy Committee) on Demand Generation.

Objectives• To understand the rationale and review what is meant by ‘vaccination demand’ and its

measurement;

• To describe promising practice is driving and sustaining demand through resilient programmes and communities;

• To identify how communities voice their agenda and what tools and mechanisms are considered most effective at accounting for community agenda;

• To share best practices in driving demand and closing immunity gaps by countries and partners (incl. CSOs)

Outcomes• The GVAP SO2 definition and indicators are reviewed and feedback is documented and

provided to the SO2 working group;

• Key stakeholders are aware of work being undertaken by governments, communities and the international partners on demand generation.

Chair Rebecca Martin, US CDC

Rapporteur Rebecca Fields, JSI

Facilitators Amy Dietterich, Gavi CSO constituencyBenjamin Hickler, UNICEFRobb Butler, WHOSharmin Zahan, BRAC Geert Top, BelgiumTsamo Louis Merlin, CameroonAnn Lindstrand, Sweden

Promising practices in driving and sustaining demand

18

Tuesday 23 June, 14:00 – 17:30

Working group #2


• Participants have improved knowledge of best practice (with a focus on country, CSO and community initiatives), new techniques and common language around demand generation.

Discussion areasA one hour discussion (prior to and immediately following coffee-break) will consider the definition being proposed for SO2 and the three indicators that the working group have proposed be tested and undergo a round of consultation with partners and countries (of which this sessions forms a part). Discussion will also consider the role of national, sub-national and community partners in capturing and acting-upon community demand. The final segment of the session will spotlight promising practice and prompt discussion around each case presented.

Detailed agenda


14.00 – 14.05 Introductory remarks and session objectives Rebecca Martin

14:05 – 14:30 Vaccination demand – key concepts, definition, and indicators – system, community and individual factors

Ben Hickler and Robb Butler

14:30 – 14:50 Hearing and acting upon the community voice/agenda – the role of CSOs

Amy Dietterich

14:50 – 15:30 Discussion: Testing the definition and SO2 indicator Rebecca Martin


16:00– 17:20 Promising practices in driving demand, listening to the community and closing the immunity gap: 6-7 ‘flash’ poster presentations (5’pres, 5’discussion) from countries• Geert Top, Belgium : maintaining high demand, keeping the spotlight on

vaccination and dealing with persistent threats on the Belgian immunization programme.

• Tsamo Louis Merlin, the Permanent Secretary of the Cameroon CSO Coalition 15%, will present on strategies to engage communities and reduce equity gaps in Cameroon

• Dr. Sharmin Zahan, the programme manager for BRAC’s International Health programmes, will present on community engagement in immunization in South Sudan.

• Ann Lindstrand, Sweden, will present on closing immunity gaps and driving demand for vaccines in underserved communities: the value of behavioural insight methodology.

17:20 – 17:30 Concluding remarks and wrap-up Rebecca Martin


Tuesday 23 June, 14:00 – 17:30

Working group #2

BackgroundOver the past decade, access to vaccines in middle-income countries (MICs) has been much debated. This focus on MICs has been fuelled by the realization that the majority of poor people and vaccine-preventable deaths are now in MICs and that MICs are far from attaining the GVAP targets. About 40% of countries classified as MICs by the World Bank are supported by Gavi in their immunization efforts: these are the countries representing the great majority of vaccine-preventable disease burden and with the biggest challenges. These countries are transitioning out of Gavi support, with over 20 countries estimated to lose Gavi support by 2020. A remaining 63 countries currently do not benefit from a unified international strategy for action. In these countries, vaccine preventable disease burden is lower, but substantial and unacceptable nonetheless. Many of these countries have strong systems and the potential to make rapid gains if key barriers are removed. For these remaining countries, a shared MIC strategy has been developed by partners in immunization; the strategy recently received a positive recommendation by the WHO Strategic Advisory Group of Expert (SAGE, April 2015). The MIC strategy will in the medium to long term also benefit countries who transition out of Gavi support.

ObjectivesThe session will aim at providing clarity around the ‘MIC issue’: what problems are these countries facing, what kind of support are they receiving? Discussion of experiences in the areas of procurement, price transparency, financing and Gavi graduation will allow participants to brainstorm around possible creative solutions moving forward.

OutcomesParticipants will have a clearer understanding of the MIC issue, the new Gavi transition policies and the newly developed partner-shared MIC strategy. Ideas to improve coordination among partners will be explored during discussions providing possible concrete next steps in this area.

Discussion areasMICs performance in immunization, evolving donor landscape, new Gavi transition policies, new partner-shared MIC strategy, access to timely and affordable supply, price transparency, immunization financing, Gavi transition challenges.


Rapporteur Heather Deehan, UNICEF

Facilitators Michel Zaffran, WHO Anneline Blankenhorn, WHO Judith Kallenberg, Gavi Heather Deehan, UNICEF Niyazi Cakmak, WHO Yosephine Prima Berliana, Indonesia

Sustainable access to vaccines in middle income countries

20

Tuesday 23 June, 14:00 – 17:30

Working group #3


Detailed agenda


Tuesday 23 June, 14:00 – 17:30

Working group #3


14:00 – 14:10 Introduction to the session: ‘the MIC issue’• Review of MIC performance against GVAP • Evolution of donor landscape

(Gavi and non-Gavi space)

Michel Zaffran

14:10 – 14:20 A partner-shared MIC strategy• Overview of current partner-wide work in

non Gavi MICs• The recently developed partner-shared MIC

strategy for MICs not supported by Gavi

Anneline Blankenhorn

14:20 – 14:30 Gavi Alliance’s work with Middle Income Countries• Issues and engagement with Gavi intermediate

MICs• Issues and engagement with Gavi graduating MICs

Judith Kallenberg

14:30 – 14:45 Timely access to affordable vaccines for MICs • Overview of current experience in the areas of

procurement for MICs (UNICEF SD, PAHO RF, EMRO PVP)

• Overview of price transparency efforts: UNICEF SD, PAHO RF, MSF, WHO V3P

Heather Deehan

14:45 – 15:30 Discussion

15:30 – 16:00 Coffeebreak

16:00 – 16:20 Sustainable immunization financing • Overview of issues with resource mobilisation

efforts and efficient use of resources in MICs• The case of EURO MICs and possible solutions

Niyazi Cakmak

16:20 - 16:30 Indonesia’s experience transitioning out of Gavi support• Overview of Gavi’s support to Indonesia• Overview of Indonesia’s performance in

immunization• Issues and possible solutions to transition

challenges (out of Gavi)

Yosephine Prima Berliana

16:30 - 17:30 Discussion and conclusions

INNOVATE

WEDNESDAY

24JUNE

Global Immunization Meeting: Protect, Innovate, Accelerate24

Agenda 08:30 - 12:30

WEDNESDAY

24JUNE Agenda


08.30 – 09.15 Feedback from Protect working groups with discussion

09.15 – 10.30

Plenary session #4

Page 26

Objective 2 of the polio eradication and endgame strategic plan • Introduction and video on Nigeria experience (Heather Deehan, UNICEF)• What was done differently with IPV introduction (Terri Hyde, US CDC)• What needs to happen for the switch to bOPV to be successful? (Diana

Chang Blanc, WHO)• How have countries used assets of the

Polio Eradication Initiative to benefit the broader immunization agenda? (Damaris Ogechi Onwuka, Nigeria)


11:00 - 11:30

Plenary session #5

Page 27

Immunization supply chain and logistics: Current challenges, innovations and future prospects • What’s happening in the world of immunization supply chain and logistics?

(Diana Chang Blanc, WHO)• Gavi Immunization Supply Chain Strategy:

Progress and next steps (Alan Brooks, Gavi)• Advocating for immunization supply chains (Jane McElligot, PATH)

11:30 - 12:00

Plenary session #6

Page 28

Integrated approaches to pneumonia and diarrhoea control in the context of maternal and child health• Introduction to integrated approaches for pneumonia and diarrhoea

control (Phanuel Habimana, WHO) • Experience in achieving integration across

the spectrum of maternal and child health (Elicah Kandinda Kamiji, Zambia)

12:00 - 12:30 Keypad quiz and teasers for afternoon group sessions

12.30 - 14.00 Lunch break

Location: Tramuntana 1 & 2 Chair: Henri van den Hombergh (UNICEF)


Agenda 14:00 - 17:30

WEDNESDAY

24JUNEAgenda


Working group #4

Page 30

Life-course approach in immunization: Successes in reaching older age groups• Second year of life platform• Adolescent vaccination platform • Maternal immunization

Henri van den Hombergh, UNICEFLaura Conklin, US CDCKaren Hennessey, WHORudi Eggers, WHO Philipp Lambach, WHO Ike Ogbuanu, WHO

Working group #5

Page 34

A vision for information systems in immunization programmes• Proposed framework for immunization data

monitoring and surveillance (Thomas Cherian, WHO)

• Gavi updates on strategic investments 2016-20 and data quality requirements (Chung Won Lee, Gavi)

• Panel discussion (Fred Osei-Sarpong, Ghana; Dafrossa Lyimo, Tanzania)

• Break-out groups

David Brown, UNICEFCarolina Danovaro, WHO Jan Grevendonk, WHO

Working group #6

Page 36

Game-changers in immunization delivery • Advances in novel vaccine delivery

technologies (Darin Zehrung, PATH) • Intradermal Patches as an emerging vaccine

delivery technology, and why MR vaccine is a good target for intradermal patches (Jim Goodson, US CDC)

• Outputs from AFRO EPI Managers’ survey (Birgitte Giersing, WHO)

• Vaccine delivery in a controlled temperature chain (Diana Chang-Blanc, WHO)

Debbie Kristensen, PATHBirgitte Giersing, WHOPeter Strebel, WHO


OutlineOver the past two years an unprecedented multi – partner effort has coordinated and supported 126 countries with the initial steps to the removal of OPV, starting with the introduction of one dose of IPV in their routine immunization programme and preparing for the withdrawal of type 2 OPV. At the same time, as the polio eradication effort comes to its conclusion, countries are increasingly exploiting the lessons learned through the eradication programme and the assets financed for that purpose to benefit a broader immunization agenda.

Objectives• Describe what new approaches were implemented to secure a successful multi partner effort

and meet extremely tight timelines for the introduction of a new vaccine in over 120 countries in less than 2 year

• Describe how polio assets have been used to benefit the broader immunization and public health agenda

• Share lessons on what has worked, what challenges remain, and what risks are these initiatives facing

Outcomes• Potential replications of the IMG structure into other immunization initiatives

• Greater understanding of the issues at Stake

• Renewed commitment for broad support

Discussion areas• Can the IMG model of collaboration used to support IPV introduction and the Switch to bOPV

be used for other types of initiatives

• Can the India experience in using polio assets be sustained in the long run, when polio funding dries up

Chair Heather Deehan

Rapporteur Michel Zaffran, WHO

Speakers Terri Hyde, US CDC Diana Chang Blanc, WHO Damaris Ogechi Onwuka, Nigeria

Objective 2 of the polio eradication and endgame strategic plan

26

Wednesday 24 June, 09:15 – 10:30

Plenary session #4


OutlineThe immunization supply chain and logistics system (ISCL) forms the backbone of national EPI programmes. As such, the objective of any functional ISCL is to deliver the ‘Right products in the right quantities in the right condition at the right place, at the right time and at the right cost’. However, ISCL systems in many countries were designed over 40 years ago and are increasingly strained by the growing demands of the EPI programme. Without further attention and investments made into these systems, the aspirations of “reaching more” with more life-saving vaccines as articulated in the Global Vaccine Action Plan will be compromised. In response to the growing recognition that immunization supply chain and logistic systems (ISCL) need greater attention and investments, global partners are mobilising a range of initiatives to better guide and support countries in designing, equipping and managing their supply chains.

Objectives• To provide an update on global initiatives to strengthen immunization supply chain and

logisitics systems

• To provide an update on proceedings at TechNet 14th Conference

• To promote the importance of investing in strengthening immunization supply chains in countries

Outcomes• Increased understanding of the challenges being faced in EPI in ISCL and strains on

the existing system

• Improved knowledge on activities being undertaken by WHO and partners to support countries in strengthening the ISCL and the TechNet platform

• Knowledge on GAVI Supply Chain Strategy and PATH advocacy initiative for iSCL

Detailed agenda

Chair Henri van den Hombergh, UNICEF

Rapporteur Diana Chang-Blanc, WHO

Speakers Diana Chang Blanc, WHO Alan Brooks, GaviJane McElligott, PATH

Immunization supply chain and logistics: Current challenges, innovations and future prospects

TIME TOPIC SPEAKER

16:00 – 16:15 What’s happening in the world of iSCL Diana Chang Blanc

16:15 – 16:30 GAVI Immunization Supply Chain Strategy: Progress and next steps

Alan Brooks

16:30 – 17:30 Advocating for immunization supply chains Jane McElligott



Plenary session #5

OutlineCurrently, pneumonia and diarrhoea are the leading killers of children under the age of five, together accounting for 24% of all child deaths globally. Evidence shows that children are dying from these preventable diseases because effective interventions are not provided equitably across all communities. Children living in poor or remote communities are most at risk, and the burden pneumonia and diarrhoea places on their families and health systems aggravates existing inequalities.

• Only 36% of infants less than 6 months of age are exclusively breastfed.

• About 58% of caregivers reported seeking appropriate care for suspected pneumonia, and proper antibiotic treatment was given for about 47% of cases.

• 49% of children with diarrhoea received oral rehydration therapy.

• Beyond adoption, the uptake of elemental zinc in the treatment of diarrhoea remains very low.

It has been estimated that the majority of diarrhoea deaths and pneumonia deaths could be eliminated through ambitious scale-up of key interventions by 2025. Efforts to scale up known effective lifesaving child survival interventions have been made in the past but have led to limited results in improving coverage (with the exception of immunization and vitamin A supplementation). In responding to this challenge, WHO/UNICEF and partners launched in April 2013, the integrated Global Action Plan for Pneumonia & Diarrhoea (GAPPD) which proposes a comprehensive approach to end preventable child deaths from these diseases by 2025. That would save the lives of more than two million children each year. However, the set goal can only be achieved through an intensified, integrated and sustained coordinated effort from child health and child health related programmes such as immunization, nutrition, WASH and environmental health.

Objectives• Review progress in implementation of integrated approaches to scale up prevention and

control of pneumonia and diarrhoea

• Identify key bottlenecks and lessons learned to accelerate progress

• Propose key actions to be implemented in priority countries to overcome current bottlenecks


Rapporteur Carsten Mantel, WHO

Speakers Phanuel Habimana, WHO Elicah Kandinda Kamiji, Zambia

Integrated approaches to pneumonia and diarrhoea control in the context of maternal and child health

28


Plenary session #6


Outcomes• Country experiences and best practices in scaling up integrated approaches to end preventable

deaths from pneumonia and diarrhoea reviewed

• Key challenges, opportunities and lessons learnt discussed and shared

• Short to medium term priority actions to accelerate progress in selected countries identified and agreed upon (Priority countries should include Afghanistan, Angola, Burkina Faso, DRC, Ethiopia, India, Kenya, Mali, Pakistan, Niger, Nigeria, South Sudan, Sudan, Uganda).

Discussion areas• How can we effectively strengthen the use of introduction of new vaccines, especially PCV and

Rotavirus as an opportunity to promote a broader child health agenda at country level e.g. promotion of care seeking and treatment of pneumonia and diarrhoea?

• What multi-sectoral actions must be taken to improve advocacy at the highest level such as Ministers of Health and other relevant line ministers (wash, indoor air pollution…), the UN Agency Heads in UNICEF and WHO at all levels, Global Partners to accelerate progress.

• How best can we advocate for multisectoral actions that improve efficiency and synergy?

• What are the practical tools to support coordination, joint planning, implementation and M&E of integrated approaches at country level

• What are the other opportunities for integrated actions? (e.g. iCCM)

• Integrated approaches lead to efficiency and synergy. How do we measure results and impact of implementation of integrated interventions?

Detailed agenda

TIME TOPIC SPEAKER

11:30 – 11:40 Introduction to integrated approaches for pneumonia and diarrhoea control

Phanuel Habimana

11:40 – 11:50 Country experience: Achieving integration across the spectrum of maternal and child health

Elicah Kandinda Kamiji




Plenary session #6

BackgroundIn 1974, the World Health Organization (WHO) established the Expanded Program on Immunization to ensure that all infants have access to six routinely recommended vaccines. As immunization systems mature and additional vaccines are incorporated into vaccination schedules, inequity of RI services by age plays a greater role in discrepancies in immunity, and the importance of immunization platforms across the life-course increases. The purpose of this workgroup session is to explore issues related to vaccine delivery to individuals outside the traditional EPI age category, including newborns, children 2-10 years old, adolescents and adults (e.g. pregnant women). The benefits of a life-course approach to immunization include building a stronger immunization platform for existing and future vaccines, providing an opportunity to catch up on vaccines missed during the first year of life and providing an opportunity to integrate with other health interventions.

The majority of countries in all WHO regions have incorporated at least one second-year vaccine into the RI schedule, ranging from 51% of countries in the African Region to 97% in the Americas Region. Repositioning immunization systems to increase focus on the second year of life platform is an opportunity to strengthen immunization systems, improve coverage and maximize the efficiency of healthcare investments.

Similarly, several vaccines are currently recommended for use in adolescents, including Hep B, Td booster, rubella, HPV, meningococcal conjugate, etc. Adding these vaccines to RI schedules raises a few issues related to the added cost of delivery, choice of delivery strategy, integration, communication and social mobilization, consent/assent for vaccination and monitoring and evaluation issues.

Finally, WHO recommendations suggest maternal immunization against influenza and neonatal tetanus. In 2013, following delays in policy development and roll-out bottlenecks, WHO’s Strategic Advisory Group of Experts (SAGE) mandated WHO’s Initiative for Vaccine Research to address implementation obstacles to maternal immunization. In 2015, SAGE further discussed the


Rapporteur Karen Hennesssey, WHOLaura Conklin, US CDC

Facilitators Rudi Eggers, WHO Elicah Kandinda Kamiji, ZambiaRobert Kezaala, UNICEFIke Ogbuanu, WHOPhilipp Lambach, WHO Kate Gallagher, LSHTMAnn Moen, US CDCScott LaMontagne, PATH Anonh Xeuatvongsa, Lao PDR

Life-course approach in immunization: Successes in reaching older age groups

30


Working group #4


relevance of promoting integration of maternal immunization into antenatal care platforms and of backing such interventions through implementation research. WHO consequently will increase its efforts to strengthen the evidence base and support implementation research.

To support the optimization and accelerated implementation of a life course approach to immunization, this session aims to gather lessons learnt and impact on coverage and system so far and to discuss implementation opportunities, knowledge gaps/needs and future directions.

Objectives• To promote awareness of the opportunities of a life-course approach to immunization

• To examine the life course approach to immunization implementation in three areas: 2YL, adolescent and maternal immunization and its impact.

• To share examples of successful life course immunization strategies that reached previously unreached populations with routine immunization (may include PIRI, CHDs, or MCHW, etc.)

• To identify implementation opportunities and bottlenecks, and explore research gaps to address these

Outcomes• Receive input on scope of 2YL activities, landscape analyses, Zambia 2YL activities

• Suggestions of countries with strong 2YL platforms to serve as case studies

• Suggestions of potential countries interested in establishing/strengthening 2YL platform

• Identify best practices for implementation of an adolescent platform for immunization

• Summary report including main success factors for rolling out maternal immunization programmes

• Checklist of priority needs and actions required to ensure the effective roll out of maternal immunization, particularly in low and middle income countries

Session Discussion Areas• Discuss scope of 2YL activities, landscape analyses, Zambia 2YL activities

• Discuss countries with strong 2YL platforms to serve as examples, case studies

• Discuss potential countries interested in establishing/strengthening 2YL platform; should be a country that does not have MSD in schedule (companion project to Zambia).

• Challenges in implementing a successful adolescent immunization platform (e.g. HPV)

• Panel discussion among HPV demo countries/partners about challenges of setting up an adolescent immunization platform

• Global and regional perspectives and guidance on maternal immunization

• Experiences on integrating maternal immunization in select countries

• Bottlenecks to implementation: What is missing to accelerate the roll out of maternal immunization programmes in low resource settings



Working group #4

Detailed agenda

TIME TOPIC SPEAKERS

14:00 – 14:50 Second year of life platform• Opening remarks: Overview of the life course

approach in immunization: strengths, challenges and opportunities + Session structure

• Introduction to 2YL • Zambia’s plans to build/strengthen a 2YL platform• Discussion on Zambia and other countries invited

to mention 2YL efforts, challenges, successes• Panel on 2YL activities: Partner 2YL plans and

activities• Discussion and other partners invited to mention

2YL activities and plans

Rudi EggersElicah Kandinda Kamiji Robert KezaalaLaura Conklin

14:50 – 15:40 Adolescent vaccination platforms• Main issues and challenges arising from promoting

the adolescent vaccination platform• Towards developing an integrated and sustainable

adolescent vaccination platform – challenges and opportunities

• Panel Q & A: HPV demo (pilot) country experiences in reaching adolescent girls – in school and out of school

• Discussion on feasibility of adolescent vaccination – lessons learned and way forward

Ike OgbuanuAnanda Amarasinghe Elicah Kandinda KamiijKate Gallagher

16:10 – 17:10 Maternal immunization• Information needs to implement maternal

immunization in countries • Roll out of maternal influenza immunization in Laos

– opportunities and challenges encountered• Integration of maternal immunization into ANC

system – experiences from Malawi • Panel discussion: Which priority activities are

required to accelerate maternal immunization roll out for LMIC?

Philipp LambachAnn MoenScott LaMontagneAnonh Xeuatvongsa

17:10 – 17:30 Discussion and conclusions Henri van den Hombergh



Working group #4 (continued)

Resources• Table 1: Summary of WHO Position Papers – Recommendations for Routine Immunization

(showing vaccination across the life course) www.who.int/immunization/policy/Immunization_routine_table1.pdf

• Supporting Second Year of Life (2YL) Vaccination/Health Visit – Zambia Proposal

• Options for linking health interventions for adolescents with HPV vaccination www.who.int/immunization/diseases/hpv/linking_h_interventions

• Comprehensive cervical cancer prevention and control - a healthier future for girls and women: WHO guidance note: www.who.int/reproductivehealth/publications/cancers/9789241505147

• Considerations regarding consent in vaccinating children and adolescents between 6 and 17 years old: www.who.int/immunization/programmes_systems/policies_strategies/consent_note

• School vaccination readiness assessment tool: www.who.int/immunization/programmes_systems/policies_strategies/school_assessment_tool/en/World Health Organization

• Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec. 2012;87:461-76.

• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season. Wkly Epidemiol Rec. 2015. www.who.int/wer/2015/wer9022.pdf


http://www.who.int/immunization/policy/Immunization_routine_table1.pdf

http://www.who.int/immunization/diseases/hpv/linking_h_interventions

http://www.who.int/reproductivehealth/publications/cancers/9789241505147

http://www.who.int/immunization/programmes_systems/policies_strategies/consent_note

http://www.who.int/immunization/programmes_systems/policies_strategies/school_assessment_tool/en/World Heal

http://www.who.int/immunization/programmes_systems/policies_strategies/school_assessment_tool/en/World Heal

http://www.who.int/wer/2015/wer9022.pdf

BackgroundThe collection, analysis, quality, and use of data to measure and improve immunization program performance have long been priority areas for country programs and immunization partners alike. Reliable and timely data is essential for meeting increased demands for evidence-based decision making, and for systems strengthening, while empowering health workers.

The systems to collect immunization data have in general adapted slowly over the last few decades, yet recently change has started to accelerate:

• Systems have been increasingly digitized, first through the use of standalone databases and systems built in MS Excel, MS Access, or EPI info, and more recently with the quick uptake of web based systems such as DHIS2.

• There is an increased desire to integrate program monitoring systems into broader health information systems, presenting its own opportunities but also challenges.

• Many high and middle income countries have gone beyond the traditional monitoring systems to implement Electronic Immunization Registries. Recently, the use and feasibility of these systems in lower income countries is being explored, and the integration with vital registration is being explored.

• Other technologies are finding their way in immunization programs. Examples include the use of mobile phone technology to monitor vaccine stocks or cold chain equipment, the use of tablets or phones to digitize survey and review data, or the use of geographical information systems to assist micro planning routine immunization activities or campaigns.

Computerization is furthermore only one aspect of better systems, which needs to go hand in hand with focused workforce development, harmonized processes, better quality controls, and a more comprehensive reflection about the role of data in immunization programs. This breakout session offers the possibility to consider future directions for immunization data and systems, and discuss what countries and partners can do to leverage them for better program performance.

Objectives• To share information about emerging initiatives to support investments in better information

systems and data

Chair David Brown, UNICEF

Rapporteur Carolina Danovaro and Jan Grevendonk, WHO

Facilitators Fred Osei-Sarpong, Ghana; Dafrossa Lyimo, TanzaniaThomas Cherian, Marta Gacic-Dobo, Carolina Danovaro, Jan Grevendonk (all WHO)Adam MacNeil, US CDC Chris Wolff and Skye Gilbert, BMGFChung-won Lee, Gavi

A vision for information systems in immunization programmes

34


Working group #5


• To obtain feedback about a common framework for immunization data monitoring, aimed at helping partners and countries to align investments and efforts towards joint objectives.

• To solicit specific recommendations from the participants about specific implementation issues, barriers and best practices

Detailed agenda


14:00 – 14:10 Welcome and introduction David Brown

14:10 – 14:40 Proposed framework for immunization data monitoring and surveillance, with guiding principles and common objectives for partner action

Thomas Cherian

14:40 – 15:00 Gavi updates: • Strategic investments 2016-20 in data related areas• Data quality requirements

Chung Won Lee

15:00 – 15:30 Country panel discussion: • What are the needs and challenges country

programs face these days, in the context of immunization information systems

• Reactions to the proposed frameworks and investments: is anything missing? What else is expected from partners?

Open discussion all participants

Fred Osei-Sarpong, GhanaDafrossa Lyimo, TanzaniaJan Grevendonk


16:00 – 17:00 Depending on the number of participants and interest, 3 or 4 break out groups from the following list:• Technical assistance: how to organize the necessary TA in areas around

data and systems assessments, as well as for the uptake of better systems and innovations?

• Integration: how can we make sure that immunization programs fully leverage the potential benefits of integrated systems? How can we make sure that immunization monitoring systems fit in better with the broader health system? What are the trade-offs between integrated versus dedicated systems and how to address these trade-offs?

• Human resource development: what needs to be done to empower program managers and health workers to use data and technology more effectively?

• Methodology for the assessment of data and systems: In the context of the Gavi data quality requirements (in-depth review, desk review), what are the available methodologies that can be relevant and what else needs to be done?

• Immunization records: the role of home based records, facility records, their importance for the program, for monitoring, and any optimization

Facilitators: Adam MacNeil, Chris Wolff, Skye Gilbert, Marta Gacic-Dobo, Jan Grevendonk

17:00 – 17:30 Report back from the break-out groups



Working group #5

BackgroundThe WHO estimates that approximately 21.8 million infants are still not fully immunized with the basic vaccines and approximately 1.5 million children under five die each year from vaccine preventable diseases. In 2012, the Global Vaccine Action Plan (GVAP) was adopted by the World Health Assembly to realise the vision to extend the full benefits of immunization to all people, regardless of their circumstances. This could be accelerated through initiatives to develop innovative technologies that have the potential to become ‘game changers’, that is by expanding the coverage and utilization of existing vaccines, or facilitating the rapid uptake and reach of new vaccines that are on the horizon.

In addition to an overview of recent advances in novel delivery technologies, this workshop will be an opportunity to ‘deep-dive’ into the current status of the controlled temperature condition (CTC) technology approval and implementation strategy for existing vaccines, as well as the emerging technology of potentially thermostable, sub-cutaneous vaccine delivery by micro-needle patch (MNP).

Objectives• To review the recent advances in innovative vaccine delivery technologies

• To understand the rationale and review the current data to support the development for the proposed intradermal patch technology, and its application to Measles/Rubella (MR) vaccine delivery

• To update on the progress of CTC approval for established vaccines, and the pipeline/strategy for upcoming vaccines

• To identify the programmatic considerations for implementing a novel vaccine delivery technology product, with CTC as an example

Outcomes• A broader awareness of the emerging delivery technologies and their potential applications

• Consideration of the programmatic issues with respect to implementing a novel vaccine delivery strategy such as controlled temperature condition

Chair Debbie Kristiansen, PATH

Rapporteur Birgitte Giersing, WHO

Facilitators Darin Zehrung, PATHPeter Strebel, WHO Jim Goodson, US CDCDiana Chang-Blanc WHO

Game-changers in immunization delivery: Where are we and what’s in the pipeline?

36


Working group #6


Detailed agenda


14.00 – 14.45 Advances in novel vaccine delivery technologies Darin Zehrung

14.45 – 15.15 Intradermal Patches as an emerging vaccine delivery technology, and why MR vaccine is a good target for intradermal patches

Jim Goodson

15.15 - 15.30 Outputs from the AFRO EPI managers’ survey on intradermal patches

Birgitte Giersing


16.00 - 16.30 Discussion on intradermal patches Peter Strebel

16:30 - 17:00 Vaccine delivery in controlled-temperature-conditions Diana Chang Blanc

17:00 - 17:30 Discussion on controlled temperature conditions Debbie Kristensen



Working group #6

ACCELERATE

THURSDAY

25JUNE


Agenda 08:30 - 12:30

THURSDAY

25JUNE


08:30 - 09:15 Feedback from Innovate workshops with discussion

09:15 - 10:00

Plenary session #7

Page 42

Achieving and maintaining maternal and neonatal tetanus elimination • Progress, remaining challenges and way forward for MNTE (Narendra

Arora, The INCLEN Trust International)• Achieving and sustaining MNTE – India country experience (Pradeep

Haldar, India)


10:30 - 11:30

Plenary session#8

Page 43

Achieving and sustaining measles and rubella elimination• Country experience Bangladesh

(Abdur Rahim, Bangladesh)• Measles and rubella elimination: Lessons learned

and strategic options going forward (Peter Figueroa, Ministry of Health Jamaica)


12:00 - 12:30 Keypad quiz and teasers for afternoon group sessions

12.30 - 13.45 Lunch break

Location: Tramuntana 1 & 2 Chair: Rebecca Martin, US CDC


THURSDAY

25JUNE

Agenda 13:45 - 17:00


Working group #7

Page 44

New tools and strategies for MNT and measles/rubella elimination • The high risk approach to maternal and neonatal

tetanus elimination (Azhar Abid Raza, UNICEF)• District level programmatic risk assessment tool for

measles (Jim Goodson, US CDC)• What’s new in the global guidelines for improving

quality of SIAs? (Alya Dabbagh, WHO)• Experience from the African Region in assessing

country readiness to conduct measles SIAs (Balsha Masresha, WHO)

• Country experience using the SIA Readiness Assessment Tool (NN Afghanistan)

Matt Hanson, BMGFKatrina Kretsinger, US CDC Robert Kezaala, UNICEF

Working group #8

Page 46

After the crisis: Immunization and post-emergency response • The impact of Ebola on EPI services in Guinea,

Liberia and Sierra Leone (Frank Mahoney, US CDC)• Challenges and strategies to restart immunization

services in Liberia (Mary Momulu, Liberia) • Overcoming geographical barriers and

functional challenges to increase vaccination coverage in post-emergency countries (Shakoor Abdul Ghafoor, Afghanistan)

• Challenges of sustaining immunization services in complex emergencies (Damaris Ogechi Onwuka, Nigeria)

Richard Mihigo, WHO Tracey Goodman, WHO

Working group #9

Page 48

Vaccine implementation lessons learned• Process evaluation and post-introduction

evaluation of PCV introduction in Mozambique (Maria Benigna Matsinhe, Mozambique)

• Design and preliminary results of PCV impact studies in Mozambique (Helio Mucavele, Betuel Sigauque, Manhiça)

• Experience with rotavirus vaccine implementation: programmatic and disease impact (Stela Dumitru Gheorghita, Moldova)

• Graduation from Gavi support – lessons learnt (NN)

Robb Butler, WHO Terri Hyde, US CDC


17:00 - 17:30 Feedback from Accelerate workshops with discussion

Workshop rapporteurs

17:30 - 18:00 Summary and draft conclusions of the Global Immunization Meeting

Jean-Marie Okwo-Bele, WHO

OutlineProgress towards the attainment of maternal and neonatal tetanus elimination is not proceeding as planned. Out of the 59 priority countries since 1999, 22 are still yet to attain elimination partly due to resource constraints to support the high-risk approach, access to the appropriate technology that can enhance reaching the difficult to access communities and lack of adequate commitment from governments.

ObjectivesTo highlight the issues including lessons learned that facilitate progress and the challenges countries are facing. This will then set the background for advocacy for government ownership and leadership and resource mobilization.

Outcomes • Global progress and challenges would be highlighted and discussed.

• Country experiences on lessons learned and remaining challenges would be presented.

• Possible way forward including innovations and use of appropriate technology would be explored and discussed.

Discussion areas• The strategies the remaining 22 countries yet to attain MNTE need to put in place to make

further progress towards reducing their risk-status for the disease.

• Need for more focus on efforts to sustain MNTE for countries that have achieved the milestone.

• Challenges to attaining and sustaining MNTE, and how these can be overcome including issues around long term predictable financing and use of appropriate technology.

Detailed agenda


Rapporteur Pankaj Bhatnagar, WHO

Speakers Narendra Arora, The INCLEN Trust InternationalPradeep Haldar, India

Achieving and maintaining maternal and neonatal tetanus elimination

TIME TOPIC SPEAKER

09.15 – 09.30 Keynote address on progress, remaining challenges and way forward for MNTE

Narendra Arora

09.30 – 09.45 Achieving and sustaining MNTE – India country experience Pradeep Haldar

09.45 – 10.00 Discussion Ahmadu Yakubu

42


Plenary session #7


OutlineEach year measles accounts for approximately 150,000 child deaths and rubella infections during pregnancy cause an estimated 100,000 cases of congenital rubella syndrome – a combined global burden that is fully preventable by equitable access to vaccination. The Global Vaccine Action Plan targets Regional elimination of measles and rubella in 5 WHO Regions by 2020. As of May 2015, the Americas has been verified to have eliminated rubella and is on the verge of verifying measles elimination. The remaining 5 Regions each have significant challenges to achieving the GVAP elimination targets.

Objectives The objectives of the session are to inform the audience of the progress and remaining challenges to achieving and maintaining regional elimination of measles and rubella. Regional and country experience (e.g., from the Americas and from large countries such as China and Bangladesh) will be presented to illustrate what it takes to achieve and maintain elimination. Preliminary results from economic modelling will be presented to contrast the benefits and costs of different approaches to achieving elimination. The potential for disease elimination goals to maintain investments in immunization and strengthening national immunization programmes will be highlighted.

Outcomes Better understanding of the strategies for measles and rubella elimination and the synergies between immunization system strengthening and disease elimination. The results of the economic modelling will stimulate discussion of the trade-offs between different approaches to achieving elimination targets.

Detailed agenda


Rapporteur Peter Strebel, WHO

Speakers Peter Figueroa, Ministry of Health JamaicaAbdur Rahim, Program Manager EPI and Surveillance, DGHS Bangladesh

Achieving and sustaining measles and rubella elimination

TIME TOPIC SPEAKER

10:30-11:00 Country experience in elimination of measles and rubella Abdur Rahim

11:00-11:30 Achieving measles and rubella elimination - lessons learned and economic considerations

Peter Figueroa

11:30-12:00 Discussion Rebecca Martin



Plenary session #8

BackgroundThe 2014 Assessment Report of the Global Vaccine Action Plan concluded that the tetanus elimination target goal has been repeatedly missed and the regional measles/rubella goals were off track. The purpose of this workshop is to highlight new tools and strategies for getting back on track towards these GVAP elimination targets.

ObjectivesThe objectives of the session are to learn from country experience and inform participants about new guidelines and tools available to achieve tetanus, measles and rubella elimination. The new tools include:

• Guidelines for MNTE pre-validation assessment

• Guidelines for introduction of MCV2

• Guidelines for introduction of rubella containing vaccines

• Programme risk assessment tool

• Global guidelines for conducting SIAs with injectable vaccines (including SIA readiness assessment)

OutcomesIncreased awareness of the new tools available to support delivery of quality immunization services both in routine and SIAs.

Chair Matt Hanson, BMGF

Rapporteur Katrina Kretsinger, CDCRobert Kezaala, UNICEF

Facilitators Azhar Abid Raza, UNICEF Jim Goodson, US CDC Alya Dabbagh, WHOBalcha Masresha, WHOAhmadu Yakubu, UNICEFNN Afghanistan

New tools and strategies for maternal and neonatal tetanus and measles/rubella elimination

44

Thursday 25 June, 13:45 – 17:00

Working group #7


Detailed agenda

TIME TOPIC SPEAKER

13:45 - 14:15 The high risk approach to maternal and neonatal tetanus elimination

Azhar Abid Raza

14:15 - 14:45 District level programmatic risk assessment tool for measles Jim Goodson

14:45 - 15:00 Discussion and conclusions Matt Hanson


15:30 - 15:50 What’s new in the global guidelines for improving quality of SIAs?

Alya Dabbagh

15:50 - 16:10 Experience from the African Region in assessing country readiness to conduct measles SIAs

Balcha Masresha

16:10 - 16:30 Country experience assessing SIA readiness NN Afghanistan

16:30 - 17:00 Discussion and conclusions Matt Hanson


Thursday 25 June, 13:45 – 17:00

Working group #7


Thursday 25 June, 13:45 – 17:00

Working group #8

BackgroundWhen there is a crisis – be it conflict, humanitarian, natural disaster, or a public health emergency of international concern (PHEIC) – the framework for the health sector response typically has three distinct phases:

1. The “emergency response” phase during which resources are rapidly mobilized, initial assessments undertaken, operational capacities and systems established, and urgent priority activities implemented.

2. The “post-emergency or early recovery” phase where efforts focus on preparedness/risk mitigation for public health threats resulting from the emergency, and restarting health services.

3. The “reconstruction/development” phase with attention on longer-term investment and planning for health system recovery.

When health services are disrupted or suspended as a result of an emergency, the risk of morbidity and mortality from vaccine-preventable diseases (VPDs) increases dramatically. Over time a decline in immunization coverage creates cohorts of susceptibles and immunity gaps which can spark disease outbreaks with devastating consequences because both the populations and health services are in a weakened state to manage. The success with which immunization activities are planned and implemented in the “post-emergency or early recovery phase” is critical to ensuring that VPD disease outbreaks are avoided. Using the examples of the Ebola outbreak in West Africa, and the conflict/ post-conflict situations in Syria and Afghanistan, the purpose of this working group session is to examine the immunization strategies that have been used to boost immunization coverage during or after an emergency crisis while longer term efforts to rebuild the health system continue.

Objectives• To provide a situation update on immunization and VPD risks in the contexts of the

West-African ebola crisis, post-conflict Afghanistan, and Syria.

• To share operational experiences and learning on the design, planning, decision-making, implementation, and performance monitoring of immunization services in post-emergency settings.

• To highlight the collaboration and role of partners for immunization in post-emergency settings.

Chair Richard Mihigo, WHO AFRO

Rapporteur Frank Mahoney, US CDC / IFRC

Facilitators Aitana Juan, MSFFrank Mahoney, US CDC / IFRCMary Momulu, LiberiaShakoor Abdul Ghafoor, AfghanistanEunice Damisa, Nigeria

After the crisis: Immunization and post-emergency response


Resources• WHO Information Note: Guidance for Immunization Programmes in the African Region in the

Context of Ebola (Revised 30 March 2015) www.who.int/csr/resources/publications/ebola/ebola-immunization-afro

• Vaccination in acute humanitarian emergencies: A framework for decision making. WHO (2013). http://apps.who.int/iris/bitstream/10665/92462/1/WHO_IVB_13.07_eng.pdf

• Meeting Report and Action Points. WHO (AFRO & EMRO) Meeting on exchange of experiences in increasing access to and demand for immunization in areas with insecurity and/or other complex circumstances. Tunis, Tunisia, 20-21 March 2014.

Thursday 25 June, 13:45 – 17:00

Working group #8

Outcomes• Increased awareness of the immunization and VPD situation in West Africa Ebola affected

countries, Afghanistan and Nigeria.

• Identification/documentation of innovative strategies and best-practices for immunization in post-emergency contexts, as well as during emergencies.

• Strengthened partnerships for future collaboration on immunization in post-emergency situations.

Discussion areas• Challenges of providing and/or planning for immunization services in post-emergency settings.

• Innovation and key factors for achieving success.

• Learning what works and what does not work.

• Engaging civil society actors in immunization delivery.

Detailed agenda


14:00 – 14:15 Purpose, objectives, and expected sesion outcomes Richard Mihigo

14:15 – 14:30 The impact of ebola on EPI services in Guinea, Liberia and Sierra Leone

Frank Mahoney

14:30 – 14:45 Challenges and strategies to restart immunization services in Liberia post-ebola crisis

Mary Momulu



16:00 – 16:15 Overcoming geographical barriers and functional challenges to increase vaccination coverage in Afghanistan

Shakoor Abdul Ghafoor

16:15 – 16:30 Challenges of sustaining immunization services in a complex emergency

Eunice Damisa

16:30 – 17:30 Discussion and conclusions Richard Mihigo

BackgroundThe past two years have seen a rapid acceleration in the introduction of rotavirus and pneumococcal conjugate vaccines in low and middle income countries, largely as a result of Gavi support. Unlike Hib and Hepatitis B vaccines, these two vaccines were unique in that they did not come in a combination with DTP vaccines and, hence, they would have brought their unique challenges for the national immunization programmes in low and middle income countries, especially those with fragile health systems. Formal evaluations both of the introduction process and the impact of the vaccines on the targeted diseases have been conducted and may hold important lessons for stakeholders that could be applied to countries that will introduce these or other vaccines in the future. As the income levels of countries that were Gavi eligible increase, they will no longer remain eligible for Gavi support and will have to assume the costs of sustaining the vaccines they introduced using domestic resources. There are important lessons to be learnt from the countries who have gone through this graduation process that could be applied to supporting other countries who go through this process and perhaps to review and refine the graduation policies.

Objectives• Share experiences on the process of introduction of rotavirus and pneumococcal conjugate

vaccines

• Share information on the methods used and findings from studies to document the impact of these vaccines

• Share experiences with the Gavi graduation process

Outcomes• Documentation of the experiences and lessons learnt with vaccine introduction, disease

impact measurement and graduation out of Gavi support

Chair Robb Butler, WHO

Rapporteur Terri Hyde, US CDC

Facilitators Terri Hyde, US CDCUmesh Parashar, US CDC Jane McElligot, PATHMaria Benigna Matsinhe, MozambiqueHelio Mucavele and Betuel Sigauque, Manhiça, MozambiqueStela Dumitru Gheorghita, MoldovaThomas Cherian, WHO

Vaccine implementation lessons learned (rotavirus, pneumococcal vaccines)

48

Thursday 25 June, 13:45 – 17:00

Working group #9


• Compare and contrast findings from different approaches to evaluating the vaccine introduction process and determine whether and how the existing post introduction evaluation tools may be modified.

Discussion areasThis sessions includes country presentations, followed by discussions including all the participating stakeholders and will focus on lessons learnt on three key issues: (1) the introduction process; (2) measurement of the impact of the vaccines on the targeted diseases; and (3) graduation from Gavi support.

Detailed agenda


13:45 - 13:50 Introductory remarks Robb Butler

13:50 - 14:05 PCV post-introduction evaluation in Mozambique Maria Benigna Matsinhe

14:05 - 14:20 Discussion Thomas Cherian

14:20 - 14:35 Overview of the design and preliminary results of PCV impact studies in Mozambique

Helio Mucavele and Betuel Sigauque


15:00 - 15:10 The PCV Technical Coordination Project Thomas Cherian


15:40 - 16:00 Experience with rotavirus vaccine implementation (programmatic and disease impact)

Stela Dumitru Gheorghita

16:00 - 16:20 Graduation from Gavi support – lessons learnt NN

16:20 - 16:50 Discussion Umesh Parashar

16:50 - 17:00 Wrap up and conclusions Terri Hyde and Robb Butler


Thursday 25 June, 13:45 – 17:00

Working group #9


Marketplace

SUBJECT DESCRIPTION ORGANIZERS

Home-based Vaccination Record Repository

Home-based vaccination records play an important role in tracking and documenting immunization services and, in some cases, additional health interventions received by individuals. If designed and used properly, the home-based vaccination record can facilitate improvements in:• Caregiver awareness, compliance and empowerment

to seek out health services• Communication between health workers and

caregivers,• Continuity and coordination of care across health

workers• Public health monitoring and reportingHome based vaccination records vary in form, content and terminology across countries. The Home-based Vaccination Record Repository (www.immunizationcards.org) maintains an electronic collection of home-based vaccination records used across the world. Its purpose is to support the free and open exchange of information related to home-based record content and design that ultimately may be useful to the improvement of child health outcomes. This exhibit provides a snapshot of the home-based records used in 122 different countries.

Marta Gacic-Dobo, WHODavid Brown, UNICEF

Display of new delivery devices

An opportunity for a ‘hands-on’ experience of some novel vaccine delivery technologies and discussion of their pros and cons.

Birgitte Giersing, WHODarin Zehrung, PATH

Immunization eLearning Initiative

Visit us for a preview of the new Immunization eLearning Initiative. This digital learning series is being developed jointly by WHO and UNICEF to provide training to immunization staff across areas of support that are considered vital to the advancement of the Global Vaccine Action Plan.

BullCity Learning

Promising practices in driving and sustaining demand

The second strategic objective of the Global Vaccine Action Plan (GVAP) calls for “individuals and communities [to] understand the value of vaccines, and demand immunization as both a right and a responsibility.” Showcasing examples from across the world, these posters describe initiatives in driving and sustaining demand, to help contribute to improved knowledge and awareness of best practices, new approaches, and shared language on demand generation.

Lisa Menning, WHO

Location: Hall Tramuntana + Foyer Tramuntana Times: during coffeebreaks


Marketplace

SUBJECT DESCRIPTION ORGANIZERS

IVAC tools Check out some of IVAC’s most widely-used tools, including VIEW-Hub, a publicly accessible interactive platform designed for stakeholders at all levels and domains to visualize real-time information relevant to accelerating and optimizing vaccine implementation.

Lois Privor Dumm, JHU

MR China country poster handouts

China: Incredible progress towards measles elimination and the new tools for high quality SIAs• Do you wish to reach at least 95% of targeted

population during your SIAs? Use the newly user-friendly “Readiness Assessment Tool”

• Are the benefits of immunization equitably extended to all people? Here is the “Supplementary Immunization Field Guide”

• Do you wish to reduce the risk of outbreaks? WHO introduces the “Measles Programmatic Risk Assessment Tool“

• Is your country ready to introduce rubella vaccine into your national Immunization program? Here is the guide

Peter Strebel, WHO

Gavi’s grant application, monitoring and review redesign

Gavi is strengthening its grant management approach, with a view to increase grant impact, better manage risk, and increase value for money. As part of this approach, important new improvements to Gavi’s routine grant monitoring and reporting are being introduced. Gavi’s poster presents the overall picture of the grant cycle from 2016 onwards and together with handouts, explains how all these changes fit together, with a particular focus on explaining two new tools - the joint appraisal and performance frameworks. As Gavi gradually introduces these changes, providing clear communications and ensuring that partners and countries understand the objectives, content and use of these new tools is critical.

Laura Craw, Gavi

CTC video screening

The Controlled Temperature Chain, CTC, is an innovative approach to vaccine management and distribution. It allows certain vaccines to be kept at temperatures outside of the traditional cold chain for a limited period of time under monitored and controlled conditions. This 3-episode film serves as a tool to promote the CTC approach among varied stakeholders. The first episode explains what CTC is, why it is useful and how it is feasible. The second features a case study of CTC implementation during a vaccination campaign in Côte d’Ivoire, providing insight on the health workers’ perspective. The third and final episode gives an outlook on the options for countries and what manufacturers can do to support countries.

Diana Chang-Blanc, WHO


By invitation

Satellite meetings

TIME & LOCATION SESSION FACILITATORS

Monday 08:30 - 10:00

Mestral 2, 3 & 4

Retreat of WHO Immunization Focal Points

Michel Zaffran, WHO

Monday 08:30 - 10:00

Llevant 1 & 2

Retreat of UNICEF Immunization Focal Points

Henri van den Hombergh, UNICEF

Monday 10:30 - 12:00

Mestral 2, 3 & 4

Joint Retreat of WHO / UNICEF Immunization Focal Points

Michel Zaffran, WHOHenri van den Hombergh, UNICEF

Monday 13:30 - 17:30

Llevant 1 & 2

Workshop: Global Routine Immunization Strategies and Practices (GRISP)

Rudi Eggers, WHO

Monday 13.30 - 17.30

Llevant 3

Meeting of Measles and Rubella Management Team

Susana Martinez-Schmickrath, WHO

Friday 09:00 - 17:00

Llevant 1 & 2

Workshop: Evidence needed to verify elimination of measles and rubella drawing on experience from Regional Verification Commissions

Alya Dabbagh, WHO

Friday 08:30 - 10:30

Llevant 3 & 4

WHO, UNICEF and Gavi Secretariat discussion on Gavi PEF

Michel Zaffran, WHOHenri van den Hombergh, UNICEFAdrien de Chaisemartin, Gavi

Friday 11:00 - 12:30

Llevant 3 & 4

WHO, UNICEF discussion on Gavi PEF

Michel Zaffran, WHOHenri van den Hombergh, UNICEF

Friday 14:00 - 18:00

Mestral 2

Workshop: Immunization Data Quality and Use, and Information Systems for Immunization

Marta Gacic-Dobo, WHOJan Grevendonk, WHO

Note: satellite sessions are by invitation only.


By invitation

Satellite meetings

TIME & LOCATION SESSION FACILITATORS

Saturday 10:00 - 16:00

Llevant 1

Workshop: Immunization Data Quality and Use, and Information Systems for Immunization (continued)

Marta Gacic-Dobo, WHOJan Grevendonk, WHO


List of participants (provisional)

Ministry of Health

Al Awaidy, SalahMinistry of Health, OmanSr Consultant Epidemiologist, Communicable Diseases Adviser to Health [email protected]

Andradas, Elena Ministry of Health, Social Services and Equity, SpainSubdirector of Health Promotion and [email protected]

Bashour HyamEMRO Regional Technical Advisory Group, SyriaRegional Verification of Elimination Status Commission (RVC)[email protected]@gmail.com

Berliana, Prima YosephineMinistry of Health, IndonesiaEPI [email protected]

Chaiyamahapurk, SakchaiMinistry of Public Health, ThailandDirector, Office of Disease Prevention and [email protected]

Crowcroft, NatashaPublic health Ontario, CanadaChief of Applied Immunization ResearchRegional Verification of Elimination Status Commission (RVC)[email protected]

Dahl-Regis, MercelineMinistry of Health, BahamasChair Regional Verification of Elimination Status Commission (RVC)[email protected]

Damisa, EuniceNational Polio Emergency Operations CentreDeputy, NigeriaDirector/Communication [email protected]

Davidkin, IrjaNational Institute for Health and welfare, FinlandSenior ResearcherRegional Verification of Elimination Status Commission (RVC)[email protected]

Devi, AnisiskaMinistry of Health, IndonesiaStaff of Sub-Directorate of [email protected]

Gheorghita, Stela DumitruNational Center of Public Health, MoldovaDeputy [email protected]

Goh, Kee TaiMinistry of Health, SingaporeSenior [email protected]

Haldar, PradeepMinistry of Health, IndiaDeputy Commissioner (Immunization)[email protected]

Kandinda, ElikaMinistry of Community Development, Mother and Child Health, [email protected]

Limia, AuroraMinistry of Health, Social Services and Equity, SpainNational Immunization Programme [email protected]

Lindstrand, AnnThe Public Health Agency of SwedenHead of the Vaccine and Register [email protected]

Lyimo, Dafrossa Ministry of Health and Social Welfare, TanzaniaIVD Programme [email protected]

Matsinhe, Maria BenignaMinistry of Health, MozambiqueNational co-Director of Health [email protected]


List of participants (provisional)

Mayanja, RobertMinistry of Health, UgandaProgramme Manager [email protected]

Momulu, MaryMinistry of Health, LiberiaEPI [email protected]

Ogechi Onwuka, DamarisNational Primary Health Care Development Agency, NigeriaAg. Director, Disease Control and [email protected]

Osei-Sarpong, FredMinistry of Health, GhanaExpanded Programme on [email protected]

Pfaff, Gunter M.Baden-Wurttemberg State Health office, GermanyDepartment Epidemiology and Health ReportingRegional Verification of Elimination Status Commission (RVC)[email protected]

Philavong, BounphengMinistry of Health of Lao PDRDirector of Centre for HIV/AIDS and [email protected]

Rahim, AbdurMinistry of Health & Family Welfare, BangladeshProgramme Manager, EPI and [email protected]

Santos Preciado, José IgnacioUniversidad Nacional Autónoma de MéxicoRegional Verification of Elimination Status Commission (RVC)[email protected]

Top, GeertAgency for Care and Health, Infectious disease control and vaccination, Prevention Division, [email protected]

Xeuatvongsa, AnonhMinistry of Hlealth, Lao PDRDeputy Director of Mother and Child center/ EPI [email protected]

Zundong, YinNational Health and Family Planning Commission of P.R. ChinaDeputy Director, Associate Professor, National Immunization [email protected]

Partners

Abou Nader, Alice JeanneMaternal and Child Survival Program / John Snow, [email protected]

Adjagba, AlexAgence de Médecine Pré[email protected]

Agocs, MaryAmerican Red [email protected]

Alsalhani, AlainMédecins sans frontiè[email protected]

Andriamitantsoa, BenjaminNational Assembly of [email protected]

Andrus, JonSabin Vaccine [email protected]

Aung, Khin Devi [email protected]

Beels, DominiqueNetwork for Education and Support in Immunisation (NESI)/University of [email protected]

Boonprasarn, JulieLions [email protected]

Boyle, ShandaBill and Melinda Gates [email protected]

Brooks, AlanGavi the Vaccine [email protected]


Carvahlo, AnaSabin Vaccine [email protected]

Chee, GraceAbt [email protected]

Conklin, LauraUS Centers for Disease Control and Prevention [email protected]

Cooper, LouisAmerican Academy of PediatricsRegional Verification of Elimination Status Commission (RVC)[email protected]@cumc.columbia.edu

Cornejo, SantiagoGavi the Vaccine [email protected]

Craw, LauraGavi the Vaccine [email protected]

Davis, RobertAmerican Red [email protected]

de Chaisemartin, AdrienGavi the Vaccine [email protected]

Dochez, CarineNetwork for Education and Support in Immunisation (NESI)/University of [email protected]

Durupt, AntoineAgence de Médecine Pré[email protected]

Fields, RebeccaMaternal and Child Survival Program / John Snow, [email protected]

Fishburn, BurkeBigThink [email protected]

Futransky, BenjaminLions [email protected]

Gilbert, SkyeBill and Melinda Gates [email protected]

Goodson, JamesUS Centers for Disease Control and Prevention [email protected]

Hanson, MattBill and Melinda Gates [email protected]

Hyde, TerriUS Centers for Disease Control and Prevention [email protected]

Jones, AndrewBill and Melinda Gates [email protected]

Juan, AitanaMédecins sans frontiè[email protected]

Kallenberg, JudithGavi the Vaccine [email protected]

Kang’ethe, AliciaClinton Health Access [email protected]

Kapuria, BhriguJohn Snow, Inc. [email protected]

Khatib-Othman, HindGavi the Vaccine [email protected]

Kretsinger, KatrinaUS Centers for Disease Control and Prevention [email protected]

Kristensen, [email protected]

Kumar, RanjanaGavi the Vaccine [email protected]

LaMontagne, [email protected]


Langenkamp, [email protected]

Le Tallec, YannClinton Health Access [email protected]

Lee, Chung WonGavi the Vaccine [email protected]

Legargasson, Jean-BernardAgence de Médecine Pré[email protected]

Levine, OrinBill and Melinda Gates [email protected]

Macneil, AdamUS Centers for Disease Control and Prevention [email protected]

Mahoney, FrankUS Centers for Disease Control and Prevention [email protected]

Malvolti, StefanoGavi the Vaccine [email protected]

Martin, RebeccaUS Centers for Disease Control and Prevention [email protected]

Mathieson, KirstenSave the [email protected]

Matzger, HelenBill and Melinda Gates [email protected]

McElligott, [email protected]

McKinney, SusanUnited States Agency for International Development [email protected]

Mengel, MartinAgence de Médecine Pré[email protected]

Moen, AnnUS Centers for Disease Control and Prevention [email protected]

Parashar, UmeshUS Centers for Disease Control and Prevention [email protected]

Pearman, JohnGavi the Vaccine [email protected]

Rabemanantena, Juares ChurchillJohn Snow, Inc./Immunization [email protected]

Salinas, DavidGavi the Vaccine [email protected]

Shen, AngelaUnited States Agency for International Development [email protected]

Sloate, LoriGavi the Vaccine [email protected]

Steinglass, RobertJohn Snow, Inc./Immunization [email protected]

Sternin, [email protected]

Stoyanov, CristinaApplied [email protected]

Vilajeliu, AlbaGavi the Vaccine [email protected]

Wallace, AaronUS Centers for Disease Control and Prevention [email protected]

Widmyer, GregBill and Melinda Gates [email protected]

Wolf, ChrisBill and Melinda Gates [email protected]


Zehrung, [email protected]

Zizzo, SaraUnited States Agency for International Development [email protected]

Academia / research institutions

Coraggio, Diane Johns Hopkins Bloomberg School of Public [email protected]

Gallagher, KateLondon School of Hygiene & Tropical Medicine [email protected]

Mitchell, AudreyJohns Hopkins Bloomberg School of Public [email protected]

Mounier-Jack, SandraLondon School of Hygiene & Tropical Medicine [email protected]

Mucavele, HelioManhica [email protected]

Privor-Dumm, LoisJohns Hopkins Bloomberg School of Public Health [email protected]

Sigauque, Betuel Manhica [email protected]

Weiss, MitchellSwiss Tropical [email protected]

Developing Countries Vaccine Manufacturers Network

Jadhav, SureshSerum Institute of India [email protected]

Tiara, DewiBio [email protected]

Wibowo, EmeliaBio [email protected]

International Federation of Pharmaceutical Manufacturers & Associations

Laughlin, LauraSanofi [email protected]

Millogo, [email protected]

Miranda, EuniceGSK [email protected]

Musunga, JohnGSK [email protected]

Popova [email protected]

Sauty, [email protected]

Civil society organizations

Dietterich, AmyInternational Federation of Red Cross and Red Crescent [email protected]

Merlin, Tsamo LouisCoalition15%[email protected] and [email protected]

Zahan, SharminBRAC [email protected]

Measles and Rubella Regional Verification of Elimination Status Commission (RVC)

Baker, Michael GeorgeUniversity of Otago, Wellingon Regional Verification of Elimination Status Commission [email protected]


Biellik, RobinRVC [email protected]

Lobanov, Andrei Deputy chair Regional Verification of Elimination Status [email protected]

Consultants/presenters

Arora, NarendraThe INCLEN Trust International [email protected]

Figueroa, PeterMinistry of Health, [email protected]

Thompson, KimKid Risk, [email protected]

UNICEF

Afsar, Oya UNICEF CEE/CIS [email protected]

Agbor, John UNICEF Nigeria [email protected]

Al-Mulla, Taha UNICEF Iraq [email protected]

Aung, Yin Yin UNICEF ROSA, Nepal [email protected]

Bediwi, HalaUNICEF Syria [email protected]

Brown, David UNICEF Programme Division, New York [email protected]

Corkum, Melissa UNICEF Nigeria [email protected]

Dao, Halima UNICEF WCARO, Senegal [email protected]

Deehan, Heather UNICEF Supply Division, Copenhagen [email protected]

Duncan, Richard UNICEF Programme Division, New York [email protected]

Guigui, Marie-Therese UNICEF WCARO, Senegal [email protected]

Hickler, Benjamin UNICEF Programme Division, New York [email protected]

Kezaala, Robert UNICEF Programme Division, New York [email protected]

Lkhagva, SelengeUNICEF Supply Division, Copenhagen [email protected]

Mehanni, Maha UNICEF Syria [email protected]

Raza, Azhar Abid UNICEF Programme Division, New York [email protected]

Rodriques, Basil UNICEF EAPRO Thailand [email protected]

Soloman, ChandrasegararUNICEF MENA, Jordan [email protected]

Toure, Brigitte UNICEF ESARO, Kenya [email protected]

Van den Endt, MayaUNICEF Programme Division, New [email protected]

Van den Hombergh, HenriUNICEF Programme Division, New [email protected]

Varkey, SherinUNICEF [email protected]


World Health Organization

Abdel Rahman, Hossam WHO [email protected]

Abdul Ghafoor, Abdul ShakoorWHO CO [email protected]

Abeysinghe NihalWHO [email protected]

Anya, BlancheWHO [email protected]

Bhatnagar, PankajWHO CO [email protected]

Biey, JosephWHO AFRO IST West [email protected]

Blankenhorn, Anne-Line HQ/IVB [email protected]

Butler, RobbWHO [email protected]

Cakmak, Niyazi WHO EURO [email protected]

Chang Blanc, DianaHQ/[email protected]

Chaudhri, Irtaza WHO [email protected]

Cherian, Thomas HQ/[email protected]

Dabbagh, AlyaHQ/[email protected]

Danovaro, CarolinaHQ/[email protected]

Eggers, RudiHQ/IVB [email protected]

Fahmy, Kamal WHO EMRO [email protected]

Fox, Kim WHO WPRO [email protected]

Gacic-Dobo, Marta HQ/IVB [email protected]

Gaudin-Billaudaz, KatiaHQ/IVB [email protected]

Giersing, Birgitte HQ/IVB [email protected]

Goodman, Tracey HQ/IVB [email protected]

Grevendonk, Jan HQ/IVB [email protected]

Habimana, PhanuelWHO AFRO [email protected]

Hennessey, KarenHQ/IVB [email protected]

Jankovic, Dragan WHO [email protected]

Kamara, LidijaHQ/IVB [email protected]

Lambach, Philipp HQ/IVB [email protected]

Mantel, Carsten HQ/IVB [email protected]


Martinez Schmickrath, Susana HQ/IVB [email protected]

Masresha, BalchaWHO AFRO [email protected]

Mayers, GillHQ/IVB [email protected]

McFarland, JeffreyWHO SEARO [email protected]

Menning, Lisa HQ/IVB [email protected]

Mihigo, Richard WHO AFRO [email protected]

Mumba, Mutale WHO AFRO IST Eastern and Southern Africa [email protected]

Ogbuanu, Ike HQ/IVB [email protected]

Okwo-Bele, Jean-Marie HQ/IVB [email protected]

Ould, Cheikh Dah WHO AFRO IST Central Africa [email protected]

Politi ClaudioHQ/IVB [email protected]

Senouci, Kamel HQ/IVB [email protected]

Shefer, Abigail WHO EURO [email protected]

Strebel, Peter HQ/IVB [email protected]

Takashima, Yoshihiro WHO WPRO [email protected]

Yakubu, Ahmadu HQ/IVB [email protected]

Zaffran, Michel HQ/IVB [email protected]

www.who. in t / immunizat ion/programmes_sys tems

global immunization meeting: protect, innovate, accelerate · location: tramuntana 1 & 2 chair:...

Documents